JESSICA MEISENHELDER: Open Payments
NPI 1447768502 · GOLDSBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,125 in 18 payments from 8 companies in 2025. Trend: 2023 $396 · 2024 $456 · 2025 $1,125
Long term medical supply or device loan: $981Food & beverage: $144
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 10 | $981 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| ARRAY BIOPHARMA INC | 2 | $30 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $18 |
| ABBVIE INC. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Incyte Corporation | 1 | $15 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
Products named: KISQALI, NINLARO, ENJAYMO, VENCLEXTA, Vyloy, LORBRENA, PEMAZYRE, BRAFTOVI.
Industry payments across NC — which companies pay providers there.
